An is a targeted treatment that combines an antibody (the 'address label') with a chemo payload (the 'medicine'). The idea is to deliver treatment more directly to cancer cells that carry a specific marker.
People sometimes think of ADCs as a bridge between targeted therapy and chemo. They still can have side effects, but the delivery method is more selective.